Program
TQB3702 tablets+Chemotherapy regimen
A development code.
In Sino Biopharmaceutical’s pipeline, BTK抑制剂
. Its studies are mostly in Lymphoma, B-Cell, led by Sino Biopharmaceutical.
Furthest: phase 2, since Aug 21, 20241 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 2since Aug 21, 2024 | Aug 21, 2024 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB3702
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 21, 2024First study: phase 2 study in Lymphoma, B-CellFirst studyNCT06566586 · 80 planned · China
TargetBeta
“BTK抑制剂”the company's pipeline, read by Claude · source
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06566586Lymphoma, B-Cell · China | 2 | Recruiting | Mar 2026 | 80 |
How it is read
Names in the registry
- “TQB3702 tablets+Chemotherapy regimen”, 1 entry
Codes read as this program: TQB3702.
Conditions, from the studies’ own filings
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.